Skip to content
2000
image of Oral Semaglutide: A Step Forward in Cardiovascular Risk Management for Type 2 Diabetes

Abstract

Recent cardiovascular outcome trials (CVOTs) have reshaped the therapeutic landscape of type 2 diabetes mellitus (T2DM), revealing that certain glucose-lowering agents, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), offer substantial cardiovascular benefits beyond glycemic control. Injectable GLP-1RAs, such as semaglutide and liraglutide, have been shown to reduce major adverse cardiovascular events (MACE), but barriers, including cost, access, and the burden of injections, persist. The SOUL trial marks a significant milestone by evaluating oral semaglutide in high-risk patients, demonstrating a 14% reduction in MACE placebo and reinforcing GLP-1RAs cardioprotective potential in an oral formulation. This advancement holds promise for patient populations underrepresented in prior trials. However, gastrointestinal side effects and strict dosing requirements challenge long-term adherence. While the findings suggest improved accessibility and real-world applicability, further comparative trials with injectables, extended follow-up, and cost-effectiveness studies are essential. As evidence evolves, oral GLP-1RAs may represent a more patient-centered approach to managing diabetes and cardiovascular risk. This perspective article aims to explore the implications of the SOUL trial, highlight ongoing challenges in adherence and implementation, and discuss the future role of oral GLP-1RAs in cardiovascular and diabetes care.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chddt/10.2174/011871529X421551250801194823
2025-08-11
2025-09-26

  • From This Site

    /content/journals/chddt/10.2174/011871529X421551250801194823
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Ferrannini E. DeFronzo R.A. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur. Heart J. 2015 36 34 2288 2296 10.1093/eurheartj/ehv239 26063450
    [Google Scholar]
  2. Mares A.C. Chatterjee S. Mukherjee D. Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity. Curr. Opin. Cardiol. 2022 37 4 350 355 10.1097/HCO.0000000000000955 35175229
    [Google Scholar]
  3. Rivera F.B. Cruz L.L.A. Magalong J.V. Ruyeras J.M.M.J. Aparece J.P. Bantayan N.R.B. Lara-Breitinger K. Gulati M. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. Am J. Prev Cardiol. 2024 18 100679 10.1016/j.ajpc.2024.100679 38779187
    [Google Scholar]
  4. Zheng Z. Zong Y. Ma Y. Tian Y. Pang Y. Zhang C. Gao J. Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduct. Target. Ther. 2024 9 1 234 10.1038/s41392‑024‑01931‑z 39289339
    [Google Scholar]
  5. Waldrop S.W. Johnson V.R. Stanford F.C. Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity. Nat. Med. 2024 30 1 22 25 10.1038/s41591‑023‑02669‑x 38172631
    [Google Scholar]
  6. McGuire D.K. Marx N. Mulvagh S.L. Deanfield J.E. Inzucchi S.E. Pop-Busui R. Mann J.F.E. Emerson S.S. Poulter N.R. Engelmann M.D.M. Ripa M.S. Hovingh G.K. Brown-Frandsen K. Bain S.C. Cavender M.A. Gislum M. David J.P. Buse J.B. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N. Engl. J. Med. 2025 392 20 2001 2012 10.1056/NEJMoa2501006 40162642
    [Google Scholar]
  7. Husain M. Birkenfeld A.L. Donsmark M. Dungan K. Eliaschewitz F.G. Franco D.R. Jeppesen O.K. Lingvay I. Mosenzon O. Pedersen S.D. Tack C.J. Thomsen M. Vilsbøll T. Warren M.L. Bain S.C. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2019 381 9 841 851 10.1056/NEJMoa1901118 31185157
    [Google Scholar]
  8. Joseph J.J. Deedwania P. Acharya T. Aguilar D. Bhatt D.L. Chyun D.A. Di Palo K.E. Golden S.H. Sperling L.S. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: A scientific statement from the American Heart Association. Circulation 2022 145 9 e722 e759 10.1161/CIR.0000000000001040 35000404
    [Google Scholar]
  9. Marso S.P. Bain S.C. Consoli A. Eliaschewitz F.G. Jódar E. Leiter L.A. Lingvay I. Rosenstock J. Seufert J. Warren M.L. Woo V. Hansen O. Holst A.G. Pettersson J. Vilsbøll T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2016 375 19 1834 1844 10.1056/NEJMoa1607141 27633186
    [Google Scholar]
  10. Spain C.V. Wright J.J. Hahn R.M. Wivel A. Martin A.A. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin. Ther. 2016 38 7 1653 1664.e1 10.1016/j.clinthera.2016.05.009 27364806
    [Google Scholar]
/content/journals/chddt/10.2174/011871529X421551250801194823
Loading
Oral Semaglutide: A Step Forward in Cardiovascular Risk Management for Type 2 Diabetes
Bentham Science Publishers ; https://doi.org/10.2174/011871529X421551250801194823
/content/journals/chddt/10.2174/011871529X421551250801194823
/content/journals/chddt/10.2174/011871529X421551250801194823
Loading

Data & Media loading...


  • Article Type:     Editorial
Keywords: GLP-1 receptor agonists ; cardiovascular outcomes ; Oral semaglutide ; SOUL trial ; medication adherence ; type 2 diabetes

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test